CAMBRIDGE, Mass., Aug. 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, prior to the open of financial markets.
Akebia will host a conference call on Thursday, August 8, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call, please dial (800) 715-9871 (USA & Canada - Toll-Free) and enter Conference ID: 4155557.
A live webcast of the conference call will be available via the Investors section of Akebia's website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia's website at http://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.14 |
| Daily Change: | 0.01 0.32 |
| Daily Volume: | 2,230,304 |
| Market Cap: | US$832.540M |
August 28, 2025 August 21, 2025 August 07, 2025 August 04, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
